Show Topics

Pharmaceuticals/Biotech/Life Sciences

20 Blog posts

Category: Intellectual Property, Pharmaceuticals/Biotech/Life Sciences

Spanish Life Sciences Trend Analysis

by - Aug 8 2017
Spain is ranked as the 10th scientific power in the world, and 5th by scientific production in the EU 15. For life sciences companies, Spain offers both Governmental and infrastructure support. The Spanish Government provides low interest credits and incentives for companies during the start-up and growth phase. The region also has a rapidly growing…

Category: Intellectual Property, Pharmaceuticals/Biotech/Life Sciences

Dutch Life Sciences Trend Analysis 2017

by - Jul 25 2017
The Netherlands is a leader in the life sciences and biotech industry, ranked as No.4 worldwide for medical technology patent applications and No. 9 worldwide for biotechnology patent applications. More than 2,500 life sciences, medical technology companies and research organisations call the country home, and the region has attracted major multinational companies, including Johnson &…
Switzerland Life Sciences Pharma Biotech Intellectual Property

Category: Intellectual Property, Pharmaceuticals/Biotech/Life Sciences

Switzerland: Life Sciences 2017 Trend Analysis

by - Jul 10 2017
Switzerland holds only 0.1% of the world’s population, but it remains a leader in wealth, exports and life sciences.  As a smaller country, Switzerland frequently looks beyond its borders, building strong international relationships and focusing heavily on exports.  Currently its largest export sector is chemical, pharmaceutical and biotech, accounting for 41% of total Swiss exports.…

Category: Intellectual Property, Pharmaceuticals/Biotech/Life Sciences

UK Life Sciences Trend Analysis 2017

by - Jun 28 2017
The UK is firmly established as a global centre for life sciences, with a strong history of innovation and entrepreneurship. Across the life science sector, almost half a million jobs are supported, with the activities of these companies directly contributing £14.5bn to the economy, and providing an additional £15.9bn indirectly. Pharmaceuticals dominate the sector, but…

Category: Anti-Corruption / FCPA, Energy, International Trade & Defense, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences

An Interview with Dr Klaus Moosmayer, Chief Compliance Officer, Siemens

by - Sep 23 2014
An Interview with Dr Klaus Moosmayer, Chief Compliance Officer, Siemens 5 September, 2014 by Ben Sharples ([email protected]), Senior Conference Producer, Legal Division, C5 Communications Dr Klaus Moosmayer, Speaker at C5’s Compliance and Legal Risk Leaders Summit Q1. – What would you say have been the key changes in the compliance officers’ role in the last 12-18…

Category: Anti-Corruption / FCPA, Pharmaceuticals/Biotech/Life Sciences

Managing bribery and corruption risk in the life sciences industry

by - May 23 2014
Managing bribery and corruption risk in the life sciences industry

Category: Advertising & Marketing, Legal Conferences, Pharmaceuticals/Biotech/Life Sciences

Sumitomo Chemical reference: When are marketing authorisations valid?

by - Jan 22 2014
By Dr Beatriz San Martín & Phil Bilney In the recent Sumitomo Chemical preliminary ruling which is of relevance not only to the chemical and agriculture industry but also to the pharmaceutical industry, the CJEU has held that a supplementary protection certificate (“SPC”) for a plant protection product (“PPP”) cannot be sought on the basis of an emergency…

Category: Expert Guest Blog Entries, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences

What constitutes a human embryo? – CJEU to revisit controversial issue

by - Jan 22 2014
Dr Beatriz San Martín Field Fisher Waterhouse LLP On 17 April the UK High Court made a reference to the Court of Justice of the European Union (“CJEU”), requesting that the term “human embryos” in Article 6(2) of the Directive 98/44/EC, commonly referred to as the Biotech Directive, be clarified.  The referral focuses on whether artificially…

Category: Expert Guest Blog Entries, Intellectual Property, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences, Telecoms & Technology

Beatriz San Martin

by - Jan 22 2014
Beatriz is a Partner in the IP & Technology Dispute Resolution Group at Field Fisher Waterhouse LLP.  She has a degree and PhD from the University of Cambridge specialising in genetics, cellular and molecular biology. Beatriz has a broad practice area advising clients in all aspects of intellectual property, with a particular focus on patents,…

Category: Expert Guest Blog Entries, Intellectual Property, Litigation, Pharmaceuticals/Biotech/Life Sciences, Telecoms & Technology

Phil Bilney

by - Jan 22 2014
Phil Bilney is a solicitor in the IP & Technology Dispute Resolution Group at Field Fisher Waterhouse LLP.  Phil advises on a wide range of IP disputes, with a particular emphasis on patent related disputes.  He has acted for a range of clients, and has a keen interest in the Life Sciences sector having studied…

Category: Intellectual Property, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences

Competition versus Patents – Anatomy of an underlying policy tension

by - Jan 21 2014
By Bertold Bär-Bouyssière[1] 2013 has seen significant tensions between antitrust enforcement and patents. The various “pay for delay” cases are the most visible development, but there are many others. increasingly, competition authorities challenge the use of patents or virtually ignore them when applying competition law. What is the ideology behind these occurrences? The short article…

Category: Anti-Corruption / FCPA, Healthcare, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences

LIFE SCIENCES – WEEKLY INDUSTRY NEWS

by - Jan 16 2014
Belarus Ambulance Doctors: Underpaid And Overworked, by Vadzim Smok, Posted on BelarusDigest Leading up to New Year’s Eve and throughout the first week of 2014, employees of the Minsk municipal ambulance service launched a protest. They are demanding a raise in salaries and improved labour conditions. The healthcare sector in Belarus remains financed by the state and has…